Ondansetron Tablets

Type of Posting: 
Revision Bulletin
Posting Date: 
30–Jun–2011
Official Date: 
01–Jul–2011
Expert Committee: 
Monographs—Small Molecules 3
Reason for Revision: 
Compliance

In accordance with the Rules and Procedures of the 2010–2015 Council of Experts, the Monographs—Small Molecules 3 Expert Committee has revised the Ondansetron Tablets monograph. The purpose for the revision is to add Dissolution Test 6 for a generic product approved by the FDA, and to correct the molecular weight conversion in all Dissolution tests.

The Ondansetron Tablets Revision Bulletin supersedes the currently official Ondansetron Tablets monograph. The Revision Bulletin will be incorporated in USP 35–NF 30.

Should you have any questions, please contact Elena Gonikberg, Ph.D. (301-816-8251 or eg@usp.org).